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According to 2011 Surveillance Epidemiology and End Re-
sults, 123,000 young adult women ages 18 to 44 are diag-
nosed with cancer every year in the United States.1,2
Furthermore, an additional 6,000 children and adolescents
are treated for cancer each year.3,4Manyof these children and
young adult women will face adverse reproductive outcomes
after treatment.5–8 Such diminished reproductive potential
after cancer treatment can negatively impact quality of life in
young survivors.8–10 From a patient perspective, studies have
indicated that the potential iatrogenic loss of fertility may
have as profound impact on young women as the cancer
diagnosis itself.11
A woman’s reproductive lifespan can be shortened after
chemotherapy or radiation because such treatments likely
decrease the number of viable eggs after treatment.6,12 In this
article, we will review: the reproductive impact of cancer
treatment and the clinical risk factors associated with such
impact. To conclude, we will discuss treatment-associated
infertility and early menopause as a model of accelerated
ovarian aging. An improved understanding of cancer treat-
ment’s ability to accelerate follicle death, decrease fecund-
ability, and initiate an earlier menopause could provide a
clinically relevant, time-shortened, and reproducible snap-









Abstract The reproductive sequelae of cancer treatments may provide an important model of
accelerated ovarian aging. Tens of thousands of women treated for cancer each year
experience infertility and early menopause as a result of treatment. A spectrum of
reproductive compromise commonly ranges from immediate menopause at the time of
cancer treatment to the less proximate outcome of early menopause in the years to
decades after treatment. A woman’s reproductive lifespan can be shortened after
chemotherapy or radiation because such treatments likely decrease the number of
viable eggs after treatment. This acceleration in the decline of the number of follicles
leads to increased rates of not only infertility and miscarriage but also early menopause,
which represents the most extreme form of accelerated ovarian aging. The degree of
reproductive impairment is dependent on chronologic age and the diagnosis or
treatment. The variation in outcomes that persist may be partially explained by
pretreatment ovarian reserve. Establishing the use of clinical predictors such as ovarian
reserve markers to effectively anticipate such outcomes is an obvious and important
keystone in the foundation of cancer survivorship research. An improved understanding
of cancer treatment’s ability to accelerate follicle death, decrease fecundability, and
initiate an earlier menopause could provide a clinically relevant, time-shortened, and
reproducible snapshot into the basic biology of ovarian aging.
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Cancer Treatment as an Accelerator of
Ovarian Age
Our understanding of how cancer treatment may affect
ovarian age continues to evolve.12–14 In the past, when
assessing the gonadotoxicity of cancer treatments, most
studies used the presence or absence of normal menses as
their primary outcome.15,16 This approach had limitations in
terms of improving our understanding of fertility and pre-
mature menopause as outcomes remote from treatment.
Albright et al first described primary ovarian insufficiency
(also known as premature ovarian failure) in 194217,18; since
then an increased understanding has been gained regarding
partial ovarian injury. Primary ovarian insufficiency can be
overt (menses are absent or irregular) or occult (the ovary is
damaged but menses remain regular).19 Clinically, young
patients treated for cancer may notice a complete loss of
menstrual function in the weeks to months around treat-
ment.18,20 However, many will sustain partial ovarian injury,
which may manifest not as immediate loss of menses, but as
infertility or early menopause.12,21,22
A key proposed mechanism for such injury to the ovary is
that cancer treatments lead to apoptotic oocyte death in
growing follicles, which accelerates more follicles to come
out of the quiescent state, and subsequently be lost to further
apoptotic cell death.12,21,23,24 The number of follicles remain-
ing in the ovaries has potential implications for predicting
reproductive outcomes. One such implication may be that as
follicle counts (ovarian reserve) diminishwith age, the quality
of oocytes also declines, resulting in an increased incidence of
infertility and miscarriage rates.25–27 As a result, in patients
that are exposed to cancer treatment, acute follicle loss can
result in accelerated reproductive decline.28 The potential
outcomes of such accelerated decline can range from subtle
changes such as infertility or early menopause in the years to
decades after treatment is completed to the most severe:
amenorrhea in the weeks to months after chemotherapy or
radiation.
Reproductive Compromise after Treatment:
A Problem of Significant Scale
Most of the aims of research about reproductive health out-
comes after cancer treatment have focused on amenorrhea as
a primary outcome and have been focused on breast cancer.
When focusing on breast cancer alone, it appears that as few
as 40% of women continue to menstruate after
treatment.1–3,5–10,19,22,29–34 When other cancer types are
included, however, a higher proportion of women continue
to menstruate after treatment. For example, two-thirds of
women from the California Cancer Registry whowere treated
with chemotherapy alone for nongynecologic malignancies
noted a continuation of menses posttreatment.15,29,35 And, in
recently submitted data from our group, 57% of women with
cervical or uterine cancers and 93% with ovarian cancers in a
California Cancer Registry survey reported the presence of
menses after fertility sparing surgery for localized disease. In
both of these groups, the persistence of menses is more
common among women who are younger at the time of
treatment (►Fig. 1).
Menses may return to women who became amenorrheic
temporarily. One-third of women noted cessation of menses
after treatment with chemotherapy alone for nongynecologic
cancers. However, half of these women noted a subsequent
return of menses. Similar rates of subsequent return of once-
absent menses were noted in a recent review by Amir
et al.8,19,22,29,30,34,36
As few as 10 to 20% of women ages 18 to 40 who were
treated with chemotherapy alone report a permanent loss of
menses shortly after treatment. Among the remaining 80 to
90% who have menses, however, elevated proportions of
infertility and early menopause were noted remote from
treatment, suggesting a role for accelerated ovarian aging
as a mediator of their reproductive health outcomes. Women
who had menses at some point after treatment for leukemia,
Hodgkin disease, non-Hodgkin lymphoma, breast cancer, and
gastrointestinal (GI) malignancies were noted to be at a
substantially increased risk of infertility over the background
rate in the United States.6,7,10,20,22,29,31,33,37 Such women
were also noted to have an age-dependent elevation in risk of
early menopause in the years to decades after treatment
(►Fig. 2).
Figure 1 With advancing age, the chance of persistent menses
decreases after exposure to chemotherapy (p < 0.05, Hodgkin
disease, breast cancer, non-Hodgkin lymphoma). Adapted from
Letourneau et al.29
Figure 2 With advancing age, the probability of early menopause
decreases after exposure to chemotherapy (p < 0.05, Hodgkin dis-
ease, non-Hodgkin lymphoma, gastrointestinal cancer; p < 0.01,
breast cancer, leukemia). Adapted from Letourneau et al.22
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Those women whose menses continue despite treatment for
cancer face an increased risk of early menopause (menses
before 45 years old) in the years to decades after treatment. In
survivors of childhood cancers, the risk of developing non-
surgical premature menopause was 13-fold higher than that
of siblings, with a cumulative incidence of 8% by age
40 years.23 Of the numerous young adult women in the
United States expected to menstruate at some point after
completion of cancer treatment, between 10 and 90% may go
on to experience early menopause. The wide variance in
outcomes may be influenced by ovarian reserve, genetic
susceptibility, age at treatment, time elapsed since treatment,
and treatment type.22,30,38–41
Multiple studies have demonstrated women that have
menses posttreatment who are younger in age have a higher
probability of chemotherapy-induced earlymenopause in the
years to decades after treatment.22,38 ►Fig. 2 illustrates age-
specific rates of early menopause in women treated with
chemotherapy for various disease types in women who had
menstruated after treatment: Hodgkin disease, non-Hodgkin
lymphoma, and GI malignancies. For instance, 18-year-old
women with non-Hodgkin lymphoma are at a fivefold in-
creased riskof experiencing earlymenopause versus their 40-
year-old counterparts.22 Unpublished data from the Califor-
nia Cancer Registry also demonstrates a significant relation-
ship between younger age at treatment and probability of
early menopause in women treated with fertility sparing
surgery and chemotherapy for gynecologic cancers who
note menses in the weeks to months posttreatment. Such
results argue for the importance of counseling younger
women about their risk of a shortened reproductive window.
It has been suggested that temporary amenorrhea in the
posttreatment period could be associatedwith a higher riskof
earlymenopause than if menses persistedwithout temporary
cessation. Reports have been conflicting, with some studies
suggesting an increased probability of early menopause after
temporary amenorrhea whereas others have not.29,38 This
discrepancy could represent a difference in ovarian response
based on treatment type, the age of the study population, or
the duration of posttreatment amenorrhea that is noted
(►Fig. 3).29 In addition, the differences in genetic variance
and ovarian reserve amongst those women who note tempo-
rary amenorrhea versus those who do not are presently not
well understood.41
Among women who have menses present after cancer
therapy, recent data suggest that infertility in the posttreat-
ment period likely portends to a higher risk for subsequent
early menopause.29 In healthy women, fecundity generally
decreases drastically and somewhat predictably approxi-
mately 10 years before the average age of menopause (51
years old) (►Fig. 4).2,3,9,15,22,29,35 Women who are still
menstruating but who have a history of posttreatment infer-
tility should be made aware that their probability of entering
menopause before the age of 45 is approximately twofold
higher (vs. if they had been able to conceive posttreatment).29
This observation should not be surprising given that other
studies in the general population have shown that, while
menses are still present, subfertility often represents the first
manifestation of incipient ovarian failure.8,11,22,29
Along with the difficult consequences of infertility, loss of
ovarian function in patients who are survivors of cancer has a
profound impact on their hormonal milieu and potentially
their subsequent risk for the development of chronic dis-
ease.42 Establishing the use of clinical predictors to effectively
anticipate such outcomes is an obvious and important key-
stone in the foundation of cancer survivorship research.
Recent studies have shown thatmeasuring ovarian reserve
markers before treatment may provide further guidance into
predicting the degree of reproductive compromise after
treatment. Evidence has shown that lower antral follicle
count (AFC) and/or anti-Mullerian hormone (AMH) are asso-
ciated with a higher incidence of posttreatment amenorrhea
(►Fig. 5).43 These observations suggest that women who
have advanced ovarian age before treatment are more likely
to experience reproductive compromise regardless of chro-
nologic age.28 This, along with genetic variance, may explain
some of the variation in reproductive impairment that we
observe for a given treatment and chronologic age.40 Other
studies have shown markers of ovarian reserve decline at
different rates depending on the gonadotoxicity of the regi-
men (►Fig. 6).44 Decanter et al published their preliminary
Figure 3 With advancing age, the chance of return of menses once
amenorrheic decreases after exposure to chemotherapy (p < 0.05,
Hodgkin disease, leukemia; p < 0.01, breast cancer, non-Hodgkin
lymphoma). Adapted from Letourneau et al.29
Figure 4 In healthy women, fecundity generally decreases approximately
10 years before the average age of menopause (51 years old) (adapted from
TeVelde et al. The variability of female redproductive ageing. Hum Reprod
Update 2002;8(2):141–154. Used with permission.62).
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results showing how AMH levels change with exposure to
chemotherapy and up to 12 months thereafter in patients
exposed to Adriamycin, Bleomycin, Vinblastine, Dacarbazine
(ABVD) and non-ABVD regimens.44 AMH levels decrease
during chemotherapy and can rebound thereafter.44,45 They
observed the rebound in ovarian reserve markers is more
dramaticwith ABVD, which suggests this regimen is less toxic
to the nongrowing pool of follicles. These findings correlate
with the higher incidence of temporary amenorrhea with the
ABVD regimens, compared with non-ABVD regimens that we
observe.44 Other studies have shown that higher doses of
alkylating agents have been correlated with decreased AMH
levels. As the gonadotoxicity of therapy increases, AMH levels
approach those of perimenopausal women (►Fig. 7).46 These
data support that AMH can detect differences in ovarian
toxicity between chemotherapy regimens. In addition, AFC
has been shown to be decrease inwomenwho are survivors of
childhood cancer treatment, despite continuation of menses,
compared with controls that were not treated for cancer.46
These observations are not surprising given that ovarian
reservemarkers are an estimate of the number of nongrowing
follicles that are remaining in the ovary.47–49
Infertility and Early Pregnancy Loss
Among women with menses present after treatment, infer-
tility rates in the years and decades after treatment are
elevated as high as two to four times the background rate
in the United States.10,22,33 Overall percentages of 12-month
infertility among women who continued to menstruate after
treatment with chemotherapy alone were 20, 18, 15, 27, and
23% for women in the California Cancer Registry with a
history leukemia, Hodgkin disease, non-Hodgkin lymphoma,
breast cancer, and GI malignancies, respectively.22 Similar
rates of infertility were seen in the Norwegian Cancer Regis-
try, in which 25% of 184 women with similar time to follow-
up for Hodgkin disease and attempting conception were
unable to conceive.32 Studies that have reported on postdiag-
nosis pregnancy rates, rather than infertility, report pregnan-
cy rates from 9 to 13% for breast cancer survivors.50–52
Although low pregnancy rates can be influenced by many
factors including age, fear of recurrence, delayed attempts at
conception, treatment-related sexual dysfunction, and diag-
nosis-related relationship instability, a major factor is the
permanent impact of adjuvant systemic therapies on ovarian
function and reserve.13,21,53
Women who experience temporary amenorrhea report
rates of infertility that may be doubled versus those whose
periods continued through chemotherapy.29 Data from the
California Cancer Registry suggest that the absence of menses
during or after their treatment is associated with a further
loss of future reproductive capacity.29 In other words, a
Figure 6 ABVD and non-ABVD regimens are shown to affect AMH levels
differently during the first 12 months after chemotherapy (adapted from
Decanter et al. Anti-mullerian hormone follow-up in young women treated
by chemotherapy for lymphoma preliminary results. Reprod BiomedOnline
2010;20(2):280–285. Used with permission.63).
Figure 7 In increasingly gonadotoxic cancer therapies, AMH levels
approach those of perimenopausal women (adapted from Garcia et al.
Impact of cancer therapies on ovarian reserve. Fertil Steril 2012;97(1):
134–140.e1. Used with Permission.64).
Figure 5 Lower AFC and AMH are associated with posttreatment
amenorrhea. AFC, antral follicle count; AMH, anti-Mullerian hormone.
(Adapted from Anderson and Cameron.43)
Seminars in Reproductive Medicine Vol. 31 No. 6/2013



















































temporary chemotherapy-induced amenorrhea may corre-
late with an independent increase in risk of infertility or
reproductive compromise. Partridge et al noted a similar
association in a prospective cohort study utilizing Interna-
tional Breast Study Group data.38
When pregnancy does occur, the risk of spontaneous
miscarriage may be elevated in those with a history of
systemic chemotherapy exposure.54 Recently submitted
data from our group also show miscarriage rates in the
California Cancer Registry which were significantly higher
among women with pregnancies after treatment for early-
stage gynecologic cancers that underwent fertility sparing
surgery than they were for nongynecologic cancers, despite
controlling for pelvic radiation. This increased rate of early
pregnancy loss after cancer treatment further supports the
notion that treatment is associated with advancement of
ovarian age. Prior studies have demonstrated an association
between decreased ovarian reserve and higher rates of
miscarriage.25–27
Older chronologic age at the time of treatment has been
associated with an increased risk of infertility after chemo-
therapy (►Fig. 8). This is likely related to age-related deple-
tion of ovarian reserve before initiation of cancer therapy.
However, an association between ovarian reserve markers
and infertility and miscarriage has yet to be clearly estab-
lished amongst a diverse group of cancers. Nonetheless, it is
reasonable to assume that such a relationship exists given the
accelerated loss in follicle count that results from the chemo-
therapy and/or radiation. An ability to better predict in-
creased risk for reproductive difficulties after treatment
could improve counseling for the 123,000 reproductive-age
women diagnosed with cancer each year in the United
States.55–57
Immediate Menopause
Aminority of women treated for cancer will not see advanced
ovarian aging manifest in a time period remote from treat-
ment. Approximately 10 to 30% of those women treated for
cancer during their reproductive years will manifest themost
severe form of reproductive compromise—immediate meno-
pause amenorrhea.22 This form of ovarian injury is manifest
by relatively fewwomenwho are treated with chemotherapy
alone, but is much more prevalent amongst women being
treated with bone marrow transplant or pelvic radiation.
Among breast cancer patients in the California Cancer Regis-
try, for example, 9% experience acute loss of menses after
treatment and no return within 1 year. Similarly, approxi-
mately 7 to 8% of women treatedwith chemotherapy alone for
Hodgkin disease noted permanent cessation of menses.22,58
Taken together, women in the United States who manifest
permanent amenorrhea at the time of cancer treatment
comprise tens of thousands of patients who experience a
similarly acute and devastating loss of ovarian function.
Radiation and various chemotherapies each differ in their
mechanism of cancer cell cytotoxicity or cell cycle inhibition
and, consequently, given treatment types exert varied effects
on ovarian function. External beam radiation induces wide-
spread DNA injury via free radical production within the
radiated field. Alkylating agents (cyclophosphamide/temozo-
lomide) lead to cross-linking of DNA strands in cell nuclei with
relatively little dependence on active cell division for their
cytotoxic effect. Each of these modalities presumably cause
more widespread ovarian damage as they significant effect
DNA stability in both growing and quiescent follicles.14 Plati-
num-containing compounds (cisplatin/carboplatin/oxalipla-
tin) may act similarly in the ovary, via DNA cross-linking.
Agents that act via cell cycle inhibition such as topoisomerase
inhibitors or anthracyclines (topotecan/doxorubicin), as well
as antimetabolites (methotrexate/fluorouracil), likely exert a
more selective effect on growing follicles. Over 80% of women
treated with external beam pelvic radiation or bone marrow
transplant will subsequently experience amenorrhea. Alkylat-
ing agents, particularly the combination regimen of oral
cyclophosphamide, methotrexate, and fluorouracil), are asso-
ciated with the highest risk of ovarian failure in patients with
breast cancer, reaching 90% in women older than 40 years.3
Conversely, regimens such as Adriamycin, vinblastine, bleo-
mycin, dacarbazine) for Hodgkin disease have been thought to
exert less gonadotoxicity, with reported acute ovarian failure
rates often less than 20%.14 This risk of amenorrhea also
increases with higher cumulative doses of chemotherapy,
particularly with alkylating drugs and when using taxanes
and anthracyclines in combination.30,36,59,60 As one ages,
smaller and smaller doses are needed to produce ovarian
failure.61 This is consistent with the observation that women
with lower ovarian reservemarkers before treatment aremore
likely to experience posttreatment amenorrhea.44,47
Treatment-Associated Infertility and Early
Menopause Model Accelerated Ovarian
Aging
Tens of thousands of women treated for cancer each year will
go on to experience infertility and earlymenopause as a result
of treatment-induced advancement of their ovarian age. This
has been demonstrated in several ways. Women exposed to
chemotherapy have lower ovarian reserve than expected for
their age group. Variability in ovarian reserve may help
Figure 8 With advancing age, the incidence of infertility increases after
exposure to chemotherapy at a greater rate than the general United States
population (p < 0.05, Hodgkin disease, breast cancer; p < 0.01, non-
Hodgkin lymphoma). Adapted from Letourneau et al.29
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account for the observed variation in rates of ovarian insuffi-
ciency in age-matched individuals who have undergone
cancer treatment.Women that receivemore toxic treatments
have lower ovarian reserve markers. These ovarian reserve
markers are correlated with the number of eggs that are
remaining in the ovary. This acceleration in the decline of the
number of follicles leads to increased rates of not only
infertility but also early menopause, which represents the
most extreme form of accelerated ovarian aging.
In Western societies during the past 50 years, increasing
educational level and participation in the labor force have
been associated with a rise in the mean age at which women
deliver their first child. Female fertility starts to decline from
the early 20s because of decreasing ovarian reserve—a term
that refers to both the quality and the quantity of the ovarian
follicle pool. Consequently, many women will be faced with
unexpected fertility problems as a result of their ovarian age.
Women with advancing ovarian age must too face the poten-
tial health consequences associated with the menopausal
transition, including osteoporosis and cardiovascular disease.
Given the tremendous cost burden on our health care
system of infertility, osteoporosis, and cardiovascular disease,
efforts made to mitigate their frequency should be lauded by
health policy makers. Unfortunately, under average circum-
stances, these outcomes and the factors (such as advancing
ovarian age) that are associated with them take years to
decades to manifest and are therefore difficult to study. An
improved understanding of the clinical consequences and
translational biology of ovarian aging provides an opportuni-
ty to make an immeasurable impact on health care costs and
outcomes. We have demonstrated in this article how cancer
treatment’s ability to accelerate follicle death, decrease fe-
cundability, and initiate an earlier menopause in tens of
thousands of women can provide a clinically relevant,
time-shortened, and reproducible snapshot into the basic
biology of ovarian aging.
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